MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

Published: Friday, February 27, 2026 at 4:03 am

Investors in Mereo BioPharma Group PLC Urged to Consider Lead Plaintiff Role in Securities Fraud Lawsuit

NEW YORK - Investors who purchased American Depositary Shares (ADSs) of Mereo BioPharma Group plc (MREO) between June 5, 2023, and December 26, 2025, are being notified of a securities fraud lawsuit. The Rosen Law Firm, a global investor rights law firm, is representing investors and has announced an important deadline for those interested in potentially leading the class action.

The lawsuit alleges that Mereo BioPharma Group plc provided investors with misleading information regarding the Phase 3 Orbit and COSMIC studies for setrusumab, a drug being tested for Osteogenesis Imperfecta (OI). Specifically, the suit claims that the company made positive statements about the drug's potential to reduce fracture rates, while simultaneously concealing adverse facts about the studies' outcomes. The primary endpoints of the studies, which aimed to reduce annualized clinical fracture rates, were not met. This alleged misrepresentation, the lawsuit contends, led investors to purchase Mereo's ADSs at inflated prices.

Investors who purchased shares during the specified period may be entitled to compensation through a contingency fee arrangement, meaning they would not pay any out-of-pocket fees or costs. The deadline to move the Court to serve as lead plaintiff is April 6, 2026. The lead plaintiff will act as a representative for other class members in directing the litigation.

The Rosen Law Firm encourages investors to select qualified counsel with a proven track record. The firm highlights its experience in securities class actions and shareholder derivative litigation, citing past successes and recoveries for investors. Investors interested in joining the class action can find more information and instructions on how to proceed through the provided contact information.

BNN's Perspective: While these types of lawsuits are common, it's crucial for investors to carefully consider their options and the potential risks and rewards. Selecting experienced legal representation is paramount. Investors should also be aware that the outcome of such cases is uncertain, and there is no guarantee of a successful recovery.

Keywords: Mereo BioPharma, MREO, securities fraud, class action, Rosen Law Firm, investor lawsuit, American Depositary Shares, ADSs, setrusumab, Osteogenesis Imperfecta, OI, Orbit study, COSMIC study, lead plaintiff, investor rights, shareholder litigation, legal action, financial news, investment, stock market.

Full Story